Edition:
United States

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

20.40USD
14 Aug 2018
Change (% chg)

-- (--)
Prev Close
$20.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
18,351
52-wk High
$23.00
52-wk Low
$8.50

Chart for

About

Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory.... (more)

Overall

Beta: 3.35
Market Cap(Mil.): $346.07
Shares Outstanding(Mil.): 17.01
Dividend: --
Yield (%): --

Financials

  CBMG.OQ Industry Sector
P/E (TTM): -- 169.61 31.56
EPS (TTM): -3.05 -- --
ROI: -74.08 1.42 12.88
ROE: -74.13 0.52 15.04

BRIEF-Cellular Biomedicine Group Qtrly Loss Per Share $0.51

* CELLULAR BIOMEDICINE GROUP REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

May 08 2018

BRIEF-Cellular Biomedicine Announces Positive Clinical Data Of Knee Osteoarthritis China Phase I Trial

* CELLULAR BIOMEDICINE GROUP ANNOUNCES POSITIVE 48-WEEK CLINICAL DATA OF ALLOJOIN™ HUMAN ADIPOSE-DERIVED MESENCHYMAL PROGENITOR CELL (HAMPC) KNEE OSTEOARTHRITIS (KOA) CHINA PHASE I TRIAL

Mar 16 2018

BRIEF-Cellular Biomedicine Group Reports Full-Year 2017 Financial Results And Recent Operational Progress

* CELLULAR BIOMEDICINE GROUP REPORTS FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

Mar 06 2018

BRIEF-Cellular Biomedicine Files For Resale Of Up To 2.9 Mln Shares By Selling Stockholders ‍​

* CELLULAR BIOMEDICINE GROUP FILES FOR RESALE OF UP TO 2.9 MILLION SHARES BY SELLING STOCKHOLDERS - SEC FILING ‍​ Source: (http://bit.ly/2oKEYbP) Further company coverage:

Mar 05 2018

Earnings vs. Estimates